Domain Not Resolving

Pound Sterling

Amazon Route 53

Squarespace Hosted

Business Management

Birgit Zech

Sakae Asanuma

Karin Kleinhans

Mathieu Bollen

Nicholas Tonks

Debora Dumont

Therese Liechtenstein

Claus Schalper

Simone Botti

Co-Founder, Chief Executive Officer

Edward Holson

Chief Scientific Officer and President US

Gerhard Müller

Co-Founder, Chief Scientific Officer

Europe, Middle East, and Africa (EMEA) Seed Stage Companies With Fewer Than 50 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Startups (Top 10K)

Europe Companies With Fewer Than 1000 Employees (Top 10K)

The Netherlands Biotechnology Companies

Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications

Seed Round - Anavo Therapeutics

Bioqube Ventures

Inkef

M Ventures

Taiho Ventures

Leiden

Zuid-Holland

The Netherlands

Europe

Anavo Therapeutics

Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US

Anavo Therapeutics Strengthens Management Team

Anavo Therapeutics Raises €8.5M; Extends Seed Round to €28M

Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic

Anavo Therapeutics–McDermott C: board, 202112– Board Chairman main org Primmune Therapeutics Inc

Anavo Therapeutics–Bioqube Ventures: investment, 202104 seed financing round totalling €20m incl co-investor Bioqube Ventures

Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall

Anavo Therapeutics wants Big Pharma to dust off the shelves in search of phosphatase drugs

Anavo Therapeutics closes $24M seed round to drug the phosphatome

United States

North America

Latvia

Palestinian Territory

Asia

Anavo Therapeutics is a global leader in unlocking the full therapeutic potential of human phosphatase biology. The company focuses on systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Mar 8, 2024 11:57 AM	cd77cc05
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 11:57 AM	1015c57c
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general	Oct 31, 2024 9:55 AM	033ac299
crunchbase profile	general	Oct 31, 2024 10:49 AM	7a7cacaf
li profile	general
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 8, 2024 11:57 AM	22fa0246
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

ANAV

COM:ANAVOTX

Anavo Therapeutics